LEVEL OF LEUKOTRIENE AND THROMBOXANE IN B LOOD AND CLINICAL-PARAMETERS OF PATIENTS WITH OSTEOARTHRITIS AND RHEUMATOID-ARTHRITIS BEFORE AND AFTER APPLICATION OF TEPOXALIN

Authors
WILLBURGER RE WITTENBERG RH BRAUCKMANNBERGER J KLEEMEYER KS HOOS R LUDWIG J BRUNNER F PESKAR BA
Citation
Re. Willburger et al., LEVEL OF LEUKOTRIENE AND THROMBOXANE IN B LOOD AND CLINICAL-PARAMETERS OF PATIENTS WITH OSTEOARTHRITIS AND RHEUMATOID-ARTHRITIS BEFORE AND AFTER APPLICATION OF TEPOXALIN, Aktuelle Rheumatologie, 21(5), 1996, pp. 238-241
Citations number
25
Categorie Soggetti
Rheumatology
Journal title
Aktuelle Rheumatologie → ACNP
ISSN journal
0341051X
Volume
21
Issue
5
Year of publication
1996
Pages
238 - 241
Database
ISI
SICI code
0341-051X(1996)21:5<238:LOLATI>2.0.ZU;2-S
Abstract
In a clinical study phase II 2 x 200 mg tepoxalin were administered or ally over 3.5 days to 7 patients with osteoarthritis (OA) and 6 patien ts with rheumatoid arthritis (RA). Leukotriene (LT) B-4 and LTC(4) rel ease from blood was decreased, thromboxane (TX) B-2 release was reduce d significantly. Relevant concentrations of tepoxalin and its metaboli te in plasma and synovial fluid were detectable. According to the visu al analog scale, pain was reduced significantly for both groups. in RA patients, the Ritchie Index, the number of swollen joints, and mornin g stiffness were reduced.